Navigation Links
First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Date:9/17/2007

for postmenopausal osteoporosis was based on the results of the Pivotal Fracture Trial, which involved more than 7,700 women. In the study, published in The New England Journal of Medicine in May 2007, Reclast was shown to increase bone strength and reduce fractures in areas of the body typically affected by osteoporosis, including the hip, spine and non- spine (i.e., hip, wrist, arm, leg, rib). Reclast is the only treatment approved to reduce the risk of fractures across all of these key sites. The study showed Reclast reduced the risk of spine fractures by 70% and hip fractures by 41% (4).

Reclast belongs to a class of drugs called bisphosphonates, which are used to treat osteoporosis, the most common metabolic bone disease affecting more than 10 million people in the US (2). Unlike oral bisphosphonate treatments, where patients take daily, weekly or monthly doses of medication, Reclast is given as a once-yearly infusion.

In July 2007, the Committee for Medicinal Products for Human Use (CHMP) also issued a positive opinion recommending approval in the European Union, under the brand name Aclasta(R). The European Commission generally follows the CHMP's recommendations and is expected to issue a final decision within three months.

Reclast is approved in more than 60 countries, including the US, Canada and the EU for the treatment of Paget's disease of the bone, the second most common metabolic bone disorder. Additional studies are ongoing to examine the use of Reclast to treat corticosteroid-induced osteoporosis, male osteoporosis and bone loss in postmenopausal women with osteopenia.

The active ingredient in Reclast is zoledronic acid, which is also available in a different dosage under the brand name Zometa(R) (zoledronic acid 4 mg) Injection for use in certain oncology indications.

Reclast is contraindicated in patients with hypocalcemia (low blood calcium) and those who are allergic to zoledronic acid. Reclast contains the same acti
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015 "Whether it,s our family, ... day." In a single sentence, Dr. ... officer at Pfizer,s Centers for Therapeutic Innovation ... fueling progress at America,s biopharmaceutical companies. ... with academia, patient foundations and the National Institutes of ...
(Date:3/26/2015)... 2015 Cardiologists at Beaumont Hospital, ... commercial implant of a device recently approved by the ... fibrillation. The Watchman Left Atrial Appendage Closure implant is ... to reduce the risk of stroke. Atrial ... more than 5 million Americans. Twenty percent of all ...
(Date:3/26/2015)... NORTH CHARLESTON, S.C. , March 26, 2015 ... issues and were told by their existing PACS vendor ... Memorial Hospital (CMH) determined that they needed a ... Clinch Memorial Hospital selected Avreo interWORKS due to ... that carries modern meaningful use standards through to ...
Breaking Medicine Technology:Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
... CITY, Calif., Nov. 12, 2010 AcelRx Pharmaceuticals, Inc. announced ... S-1 with the U.S. Securities and Exchange Commission (SEC) relating ... common stock. All shares of the common stock to be ... Piper Jaffray & Co. is acting as sole ...
... FARMINGDALE, N.Y., Nov. 12, 2010 Misonix, Inc. (Nasdaq: ... the art, ultrasonic medical device technology, which worldwide is ... for the first fiscal quarter ending September 30, 2010. ... and Richard Zaremba, Senior VP and Chief Financial Officer, ...
Cached Medicine Technology:Misonix Reports First Quarter Fiscal 2011 Financial Results 2Misonix Reports First Quarter Fiscal 2011 Financial Results 3Misonix Reports First Quarter Fiscal 2011 Financial Results 4Misonix Reports First Quarter Fiscal 2011 Financial Results 5Misonix Reports First Quarter Fiscal 2011 Financial Results 6
(Date:3/27/2015)... The 2015 Deep Market Research Report ... in-depth study on the current state of the ... on the Chinese situation. , The report provides ... classifications, applications and industry chain structure. The Glutathione ... and Chinese domestic situations including development trends, competitive ...
(Date:3/27/2015)... Canadian Cannabis Clinics ( http://www.cannabisclinics.ca ), Canada’s ... medical cannabis as a treatment for patients has ... dedicated to providing access to safe medical marijuana ... searching for medical marijuana treatment in legal medical ... domain for Canada. , With the partnership ...
(Date:3/27/2015)... “ VXi BlueParott Reveal ” was ... Report, which features the latest and coolest technology products ... special reporter for NewsWatch, conducted the review and shared ... eliminating 90% of ambient noise. , Today, business is ... are important to any professional, voice calls are just ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In light ... (case number 1:15-cv-10429, U.S. District Court, District of Massachusetts; ... the Eastern District of Pennsylvania), the San Diego personal ... Helbock, A.P.C. are announcing that they are available to ... of women who were prescribed Zofran while pregnant and ...
(Date:3/26/2015)... Elfster.com, the top-rated Secret Santa generator, is proud ... capabilities to its leading Secret Santa list technology. A ... one creates of things to do before one dies, ... name. Nowadays many millennials are creating summer bucket ... , "We are greatly expanding our technology to new ...
Breaking Medicine News(10 mins):Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3Health News:Canadian Cannabis Clinics (CCC) to Join the Canada.MarijuanaDoctors.com Network 2Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:The Law Office of Melinda J. Helbock, A.P.C. Announces That It Is Now Accepting Case Reviews for Potential Zofran Birth Defect Lawsuits 2Health News:Plans for Bucket List Generator - Just In Time for Summer - Announced by Elfster 2
... 9 ULURU Inc. (NYSE Alternext: ULU) today announced the ... the Company effective immediately. Following his resignation as Chief ... Director of the Company.Renaat Van den Hooff has been appointed ... President and Chief Executive Officer. Mr. Van de Hooff ...
... /PRNewswire/ -- SecureWorks(R), one of the ... with Columbian-based ETEK International to extend its security services ... One of South America,s leading security providers, ETEK will ... include, among others, Intrusion Prevention and Detection, Security and ...
... March 9 Based on its recent analysis ... Sullivan recognizes ValveXchange, Inc. with the 2009 North ... Year Award for developing the innovative ValveXchange Heart ... valve, the patented system promises to mitigate the ...
... March 9 ProteoTech Inc. announced today that ... Dr. Luke Esposito, Director of In Vitro Screening, ... Parkinson,s Diseases, to be held in Prague, Czech Republic, March ... Snow will give an oral presentation discussing promising results pertaining ...
... Tenn., March 9 Brookdale Senior Living Inc. ... Bill Sheriff, Chief Executive Officer, and Mark Ohlendorf, Co-President ... the Company at the Barclays Capital Global Healthcare Conference ... beginning at 4:15 p.m. Eastern Time.The presentation is being ...
... March 9 DURECT Corporation (Nasdaq: DRRX ... will be presenting at the Cowen and Company 29th ... a.m. EDT. The conference is being held at ... live audio webcast of the presentation will be available ...
Cached Medicine News:Health News:ULURU Inc. Announces Senior Management Change 2Health News:SecureWorks Partners With ETEK International to Provide Security Services to the South American and Latin American Markets 2Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 2Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 3Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 4Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 5Health News:ProteoTech to Present at 9th International Conference for Alzheimer's and Parkinson's Disease - Prague, Czech Republic, March 11-15, 2009 2Health News:DURECT to Participate in Cowen and Company Healthcare Conference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: